Andy Pasternak - 13 Dec 2022 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co

Signature
/s/ Patrick McIlvenny, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
13 Dec 2022
Net transactions value
-$2,710,802
Form type
4
Filing time
14 Dec 2022, 16:10:57 UTC
Previous filing
02 Nov 2022
Next filing
29 Dec 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Options Exercise $686,370 +23,251 +57% $29.52 64,216 13 Dec 2022 Direct
transaction HZNP Ordinary Shares Sale $2,618,207 -23,251 -36% $112.61 40,965 13 Dec 2022 Direct F1
transaction HZNP Ordinary Shares Sale $778,965 -6,918 -17% $112.60 34,047 13 Dec 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Stock Option (Right to Buy) Options Exercise $0 -23,251 -100% $0.000000* 0 13 Dec 2022 Ordinary Shares 23,251 $29.52 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.555 to $112.6701 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.5950 to $112.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The stock option is fully vested and exercisable.